Addex Therapeutics Ltd

ADXN

CH0029850754

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 16:30:09 02/07/2024 BST			5-day change	1st Jan Change
0.06 ^CHF	+3.45%		-0.33%	+30.43%

06-06	Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024
06-06	Addex Therapeutics' Q1 Net Loss Widens; Revenue Down	MT

Addex Therapeutics : Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter's Option to Purchase Additional Securities

January 11, 2021 at 09:00 pm

(MORE TO FOLLOW) Dow Jones Newswires

January 11, 2021 16:00 ET (21:00 GMT)

Latest news about Addex Therapeutics Ltd

Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024	06-06
Addex Therapeutics' Q1 Net Loss Widens; Revenue Down	06-06	MT
Addex to Present at BioEURquity Europe 2024	05-08	DJ
European Equities Traded in the US as American Depositary Receipts Decline	04-30	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	04-29	MT
Sector Update: Health Care	04-29	MT
Top Midday Decliners	04-29	MT
Addex Therapeutics Shares Plunge as Phase 2 Study of ADX71149 Falls Short of Primary Goal	04-29	MT
Tech Rally Subsides as US Equity Futures Waver Pre-Bell	04-29	MT
Top Premarket Decliners	04-29	MT
Addex Therapeutics Shares Plunge Premarket on Epilepsy Study Failure	04-29	DJ
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study	04-29	CI
Top Premarket Decliners	04-24	MT
Transcript : Addex Therapeutics Ltd, 2023 Earnings Call, Apr 18, 2024	04-18
Addex Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
Addex Therapeutics Logs Decline in FY23 Net Loss; Revenue Rises	04-18	MT
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update	04-18	DJ
ADRs End Higher; Biophytis Climbs 30%	04-09	DJ
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	04-09	MT
Top Premarket Gainers	04-09	MT
ADRs Advance, Eco Wave Power Global AB Climbs 213.4%	04-08	DJ
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket	04-03	MT
Top Premarket Gainers	04-03	MT
Addex Therapeutics Announces the Launch of Neurosterix, Company Focused on Developing Allosteric Modulators for the Treatment of Underserved Neurological Disorders	04-03	CI
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders	04-03	DJ

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Companyâs clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinsonâs disease and mGlu3 PAM for neurodegenerative disorders.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Addex Therapeutics Ltd

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

0.06 CHF

Average target price

0.16 CHF

Spread / Average Target

+166.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ADDEX THERAPEUTICS LTD	+30.43%	6.31M
MODERNA, INC.	+17.72%	44.44B
IQVIA HOLDINGS INC.	-10.33%	37.99B
LONZA GROUP AG	+37.55%	37.75B
ALNYLAM PHARMACEUTICALS, INC.	+29.36%	30.78B
CELLTRION, INC.	-8.44%	27.38B
ICON PUBLIC LIMITED COMPANY	+12.45%	26.17B
UNITED THERAPEUTICS CORPORATION	+44.19%	14.15B
MEDPACE HOLDINGS, INC.	+31.93%	12.59B
BIO-TECHNE CORPORATION	-7.67%	11.28B

Other Biotechnology & Medical Research

Addex Therapeutics Ltd

Equities

ADXN

CH0029850754

Biotechnology & Medical Research

Addex Therapeutics : Successfully Completes $11.5 Million Capital Increase Including Full Exercise of Underwriter's Option to Purchase Additional Securities

Latest news about Addex Therapeutics Ltd

Chart Addex Therapeutics Ltd

Company Profile

Income Statement Evolution

Ratings for Addex Therapeutics Ltd

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research